SunWay Biotech Co

SunWay Biotech Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of SunWay Biotech Co (1271.TWO) as of Oct 15, 2026 is 29.42. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 105.19 — a change of -72.04% (lower).

P/FCF

29.42

YoY

-72.04%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of SunWay Biotech Co is 2025 29.42 . P/FCF (Price-to-Free-Cash-Flow Ratio) of SunWay Biotech Co was 2024 105.19 . It decreases by -72.04% lower compared to the previous year.

The SunWay Biotech Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2017
-45.62 TWD
Jan 1, 2018
-155.09 TWD
Jan 1, 2020
19.41 TWD
Jan 1, 2021
23.16 TWD
Jan 1, 2022
87.43 TWD
Jan 1, 2023
358.77 TWD
Jan 1, 2024
105.19 TWD
Jan 1, 2025
29.42 TWD
The SunWay Biotech Co P/FCF history
YEARP/FCFYoY
29.42-72.04%
105.19-70.68%
358.77+310.36%
87.43+277.46%
23.16+19.34%
19.41-112.51%
-155.09+239.98%
-45.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on January 18, 2021, with its ticker listed as 1271.TWO and ISIN TW0001271005. SunWay Biotech focuses on the research, development, manufacture, and sale of health food products, particularly those derived from red yeast. The company's primary products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their health benefits. These products are designed to support digestive health, improve the bacterial ecology of the digestive tract, regulate immunity, and address allergies. SunWay Biotech operates in both domestic and international markets, distributing its products globally. The company's website is https://sunway.cc/, where further information about its offerings can be found. SunWay Biotech is categorized under the Health Care sector, specifically within the Pharmaceuticals industry. The company's business model centers on the production and sale of health food supplements, emphasizing natural ingredients and their functional benefits. It does not provide information on specific founding year, key personnel, or financial figures beyond its IPO date. The company's activities are strictly limited to the development and distribution of health food products without mention of additional services or product lines. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of SunWay Biotech Co is 29.42 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of SunWay Biotech Co changed from 105.19 to 29.42, representing a -72.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s SunWay Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — SunWay Biotech Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — SunWay Biotech Co